3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
4
Breast Neoplasms
3
Melanoma
2
Colorectal Neoplasms
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Resectable Localized Prostate Cancer
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Liver Neoplasms
1
Klatskin Tumor
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Glioma
1
Gastrointestinal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
Injections
6
pembrolizumab
5
toripalimab
3
tislelizumab
3
senaparib
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
cemiplimab
1
cedazuridine
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Ultrasonography, Doppler
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumor
×
Hydroxychloroquine
×
1 year
×
Clear all
No trials found.